IL13 and central nervous system cancer: Expanded ex vivo, IL13(E13Y)-zetakine+ CTL retain MHC-independent IL13Rα2-specific anti-glioma cytolytic activity, maintain CAR-regulated Tc1 cytokine secretion and proliferation, and mediate regression of established human glioblastoma xenografts in vivo[12].